Key result
Intensive glucose control did not reduce cardiovascular events in long-duration type 2 diabetes, though early intensive therapy in UKPDS showed a 15% reduction in myocardial infarction risk.
Why the study?
Does intensive glucose control reduce cardiovascular complications in patients with type 2 diabetes?
Does intensive glucose control reduce cardiovascular complications in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
While early intensive glucose control may offer a legacy effect in reducing MI risk, intensive therapy in long-standing type 2 diabetes does not appear to reduce CVD events and may increase mortality.
Cardiovascular disease (CVD) is a major cause of death in patients with type 2 diabetes. Unclear, however, is the effect of intensive therapy in reducing the development of cardiovascular complications. The UK Prospective Diabetes Study (UKPDS), involving patients with newly diagnosed disease, showed a nonsignificant trend in the reduction of rates for myocardial infarction (MI) (1). However, data 10 years after cessation of the trial showed a 15% reduction in the risk of MI for those in the original intensive therapy group (2). This benefit from early intensive therapy persisted despite the fact that the within-trial differences for A1C between the intensive and conventional therapy groups were lost within 1 year of completion of the trial. The sustained benefit from early aggressive treatment is referred to as the legacy effect or metabolic memory. The question of more intensive therapy and reduction in cardiovascular complications was addressed for people with type 2 diabetes of long duration in three other studies (i.e., the Action to Control Cardiovascular Risk in Diabetes [ACCORD] [3], the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation [ADVANCE] [4], the Veterans Affairs Diabetes Trial [VADT] [5]). Although the three studies utilized different patient cohorts, with varying durations of diabetes (ACCORD, 10 years; VADT, 11.5 years; and ADVANCE, 8 years) and had different treatment regimens, the results of these trials indicated that intensive glucose control did not reduce CVD events. In fact, the ACCORD trial was terminated early because an increased rate of mortality was found to be associated with intensive control of hyperglycemia (6). A higher rate of mortality for those on intensive treatment was not, however, found in ADVANCE and VADT. Recent articles from the ACCORD trial, by Pop-Busui et al. (7) and Calles Escandon et …
No takes yet. Share an insight, caveat, or question.
Vinik et al. (2010) conducted an editorial in Type 2 diabetes. Intensive glucose control vs. Conventional therapy was evaluated. Intensive glucose control did not reduce cardiovascular events in long-duration type 2 diabetes, though early intensive therapy in UKPDS showed a 15% reduction in myocardial infarction risk.
Synapse has enriched 10 related papers. Consider them for comparative context: